Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PBYI | US
0.05
2.04%
Healthcare
Biotechnology
30/06/2024
30/08/2024
2.50
2.47
2.52
2.40
Puma Biotechnology Inc. a biopharmaceutical company focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib intravenous) and PB357. It has a license agreement with Pfizer Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd. CANbridge BIOMED Limited Pint Pharma International SA Knight Therapeutics Inc. Pierre Fabre Medicament SAS and Bixink Therapeutics Co. Ltd. The company was founded in 2010 and is headquartered in Los Angeles California.
View LessValue Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
71.3%1 month
118.0%3 months
87.6%6 months
78.6%13.16
8.10
2.54
2.03
0.48
3.56
0.57
0.03
31.10M
122.62M
122.62M
-
-4.63
-78.10
-13.70
22.10
10.05
9.62
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.47
Range1M
1.74
Range3M
1.74
Rel. volume
0.76
Price X volume
821.07K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
QSI | QSI | Biotechnology | 0.9468 | 134.79M | -2.44% | n/a | 0.71% |
Kodiak Sciences Inc | KOD | Biotechnology | 2.51 | 132.06M | 1.21% | n/a | 81.94% |
INmune Bio Inc | INMB | Biotechnology | 6.62 | 130.96M | -3.50% | n/a | 14.65% |
Nuvectis Pharma Inc. | NVCT | Biotechnology | 6.96 | 129.82M | 2.50% | n/a | 0.00% |
Inventiva S.A | IVA | Biotechnology | 2.265 | 125.13M | -5.23% | n/a | -115.26% |
Adagene Inc. | ADAG | Biotechnology | 2.8 | 123.96M | -3.45% | n/a | 36.74% |
Repare Therapeutics Inc | RPTX | Biotechnology | 2.91 | 123.52M | -3.32% | n/a | 1.07% |
ALXO | ALXO | Biotechnology | 2.32 | 122.20M | 0.87% | n/a | 10.97% |
Seres Therapeutics Inc | MCRB | Biotechnology | 0.8006 | 121.48M | 1.34% | n/a | -244.19% |
Eton Pharmaceuticals Inc | ETON | Biotechnology | 4.6 | 118.85M | 0.00% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Emmis Communications Corporation | EMMS | Broadcasting - Radio | 4.7 | 57.98M | -1.05% | n/a | 54.59% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 3.56 | 0.97 | Expensive |
Ent. to Revenue | 0.57 | 3,681.29 | Cheaper |
PE Ratio | 13.16 | 39.83 | Cheaper |
Price to Book | 2.54 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 87.59 | 76.13 | Par |
Debt to Equity | 2.03 | -2.05 | Expensive |
Debt to Assets | 0.48 | 0.25 | Expensive |
Market Cap | 122.62M | 4.04B | Emerging |